Notably, phospho-PLN (pPLN) protein levels showed a tendency of decrease in the CKD and mirabegron-treated CKD groups compared to the sham-operated group (p = 0.157 and p = 0.137, respectively, unpaired t-test) (Fig. 5g, Supplementary Fig. S11, and S12). This evidence concerns the gene PLN and chronic kidney disease.